Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Up 392.0% in July

Key Points

• Inventiva S.A. Sponsored ADR (NASDAQ:IVA) experienced a dramatic **increase in short interest** of 392.0% in July, rising from 7,500 shares to 36,900 shares.
• Institutional investors, including Wealth Enhancement Advisory Services LLC, **raised their stakes** in Inventiva by 54.5% in the second quarter, reflecting growing interest in the company.
• Inventiva's stock is currently trading at **$3.22**, with a one-year range fluctuating between **$1.53** and **$4.05**.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) was the recipient of a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 36,900 shares, agrowthof392.0% from the June 30th total of 7,500 shares. Based on an average daily trading volume, of 19,400 shares, the short-interest ratio is presently 1.9 days. Based on an average daily trading volume, of 19,400 shares, the short-interest ratio is presently 1.9 days.

Inventiva Stock Performance

Shares of NASDAQ:IVA traded up $0.10 on Wednesday, hitting $3.35. The company's stock had a trading volume of 20,912 shares, compared to its average volume of 16,409. The company has a 50-day simple moving average of $3.28 and a 200 day simple moving average of $3.10. Inventiva has a 1 year low of $1.53 and a 1 year high of $4.05.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Inventiva stock. Wealth Enhancement Advisory Services LLC lifted its position in Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) by 54.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,558 shares of the company's stock after acquiring an additional 5,843 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Inventiva were worth $50,000 as of its most recent SEC filing. Institutional investors own 19.06% of the company's stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.